問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD6402C00001
Completed

2021-05-18 - 2023-12-31

Phase II

Terminated10

  • Trial Applicant

    PAREXEL INTERNATIONAL CO., LTD.

  • Sponsor

  • Trial scale

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator 翁國昌 Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator I-Chang Hsieh Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Heng-Chih Pan Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Ming-Ju Wu Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Hsi-Hsien Chen

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator VIN-CENT Wu Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 洪崇烈醫師 Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 鄭本忠 Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Chern-En Chiang Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Tsung-Hsien Lin Division of Cardiovascular Diseases

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    540 participants